The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
The Japanese cost-effectiveness assessment (CEA) scheme should be applied not only to the price adjustments of drugs and medical devices but also to their reimbursement decisions once a credible system is established, with current uncertainties resolved, Shoji Kono, director of…
To read the full story
Related Article
- Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
April 5, 2019
- Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
April 3, 2019
- Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
March 29, 2019
- JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
March 7, 2019
ORGANIZATION
- JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…